Cargando…
Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa). Current clinically used antiandrogens such as flutamide, bicalutamide, and newly approved enzalutamide mainly target the hormone binding pocket (HBP) of AR. However, over time, drug resistance i...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371693/ https://www.ncbi.nlm.nih.gov/pubmed/25852559 http://dx.doi.org/10.3389/fphar.2015.00057 |